Status:
COMPLETED
Study of Escitalopram in Adult Patients With Major Depressive Disorder
Lead Sponsor:
Forest Laboratories
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed ...
Eligibility Criteria
Inclusion
- Patients must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder.
- The patient's current depressive episode must be at least 12 weeks in duration.
Exclusion
- Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.
- Patients who currently meet DSM-IV criteria for: a. bipolar disorder; b. schizophrenia or any psychotic disorder; c. obsessive-compulsive disorder; d. mental retardation or any pervasive developmental disorder or cognitive disorder.
- Patients who are considered a suicide risk.
- Patients with a history of seizure disorder, or any history of seizure, stroke, significant head injury, or any other condition that predisposes toward risk of seizure.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00108979
Start Date
March 1 2005
End Date
July 1 2006
Last Update
March 5 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Southwest Health, Ltd.
Phoenix, Arizona, United States, 85016
2
Summit Research Network
Okemos, Michigan, United States, 48864
3
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
4
Summit Research Network
Portland, Oregon, United States, 97210